Eversense Is Putting Glycemic Goals Within Reach
Eversense Is Putting Glycemic Goals Within Reach
Acting on continuous insights
Exceptional real-world time in target
59%-69% time in target4
Learn More
Improved self-management
HbA1C reduction across multiple pivotal studies1-3
0.5% HbA1C reduction2
Learn More
What is Long Term CGM?
-
Longer wear time
- 92% industry-leading adherence across 3 pivotal trials.1,2,3
- Fully implantable 180-day sensor.
- Continuous readings and alerts around the clock.
Greater insight
- Exceptional accuracy, especially in the 2.2-3.3 mmol/L range.4
- Charts, graphs and in-app reports to improve glycemic awareness.
- Three types of alerts (audio, on body vibe and mobile text) to guide safe management.
Fewer obstacles
- No twice-monthly sensor replacement.
- Near-real time feedback to help predict and monitor trends.
- Detects 95% of hyper/hypo events in 15 minutes.5
Improved self-management
- Exceptional 59-69% real-world time in target.1
- Demonstrated eHbA1c of 6.9%1, below recognized treatment targets.6
- Improved control reduces health risks and complications.7
1 Christiansen MP. PRECISION. Diabetes Technology & Therapeutics. Volume 21, Number 5, 2019. 2 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 3 Kropff J, Choudhary P, Neupane S, et al. PRECISE. Diabetes Care. 2017;40(1):63-68.= 4 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 5 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206.
MKT-001309 Rev1
